Singapore markets open in 8 hours 2 minutes

ABBV Mar 2024 190.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
34.000.00 (0.00%)
As of 02:42PM EST. Market open.
Full screen
Loading interactive chart…
  • Yahoo Finance Video

    AbbVie acquiring Cerevel Therapeutics in $8.7B deal

    AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.

  • Reuters

    AbbVie to focus on smaller deals after buying spree

    "I would not anticipate similar sized transactions for the foreseeable future," said AbbVie's Chief Operating Officer Robert Michael on a conference call, referring to the company's $8.7 billion buyout of Cerevel Therapeutics announced on Wednesday. AbbVie said it expects to return to "robust growth" in 2025, after its recent buying spree.

  • Motley Fool

    Is AbbVie Stock a Buy Now?

    Leading healthcare company AbbVie (NYSE: ABBV) appears to be hungry for deals to help it diversify its revenue streams. One example of this came in 2020 when it closed on a massive $63 billion acquisition of Botox maker Allergan. To further diversify its operations, the company recently announced another acquisition.